According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending for the first time, according to a March 25 report from Evernorth. The ...